JP Morgan raised the price target for the G1 Therapeutics Inc. (NASDAQ:GTHX) stock from “an Underweight” to “a Neutral”. The rating was released on January 30, 2023, according to finviz. We previously noted in another research note published on January 03, 2023 by Needham that reiterated the stock to a Buy with a price target of $31 for GTHX stock. The research report from JP Morgan has downgraded the stock from Neutral to Underweight, with a price target set at $19. The stock was resumed by BTIG Research, who disclosed in a research note on October 15, 2021, to Buy and set the price objective to $51. In their research brief published September 30, 2021, JP Morgan analysts downgraded the G1 Therapeutics Inc. stock from Overweight to Neutral with a price target of $20.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of G1 Therapeutics Inc. (NASDAQ:GTHX) dipped -2.14% to close Thursday’s market session at $3.20, lower as compared to yesterday’s close. The stock price fluctuated between $3.0714 and $3.27 throughout the trading session with the volume trading being 1102819 shares, which represented a significant variation when compared to the three months average volume of 1.28 million shares. The firm’s stock price fluctuated 1.59% within the last five trades and -7.51% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -81.17% in the last 6 months and -47.45% was subtracted to its value over the previous 3 months. GTHX stock is trading at a margin of -9.50%, -39.43% and -60.80% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
As of the close of trading, GTHX deals in the Healthcare domain. The stock is trading -81.70 percent below its 52-week high and 8.47 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -66.1. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does G1 Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $170.14 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3.32 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.16, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.90 percent of G1 Therapeutics Inc. shares are owned by insiders, and 51.30 percent are held by financial institutions. Malik Rajesh, the Chief Medical Officer at G1 Therapeutics Inc. (GTHX) has sold 729 shares of firm on Jan 05 at a price of $5.41 against the total amount of $3942.0. In another inside trade, Hanson James S., General Counsel of G1 Therapeutics Inc. (NASDAQ:GTHX) sold 729 shares of the firm on Jan 05 for a total worth of $3942.0 at a price of $5.41. An inside trade which took place on Jan 05, CFO of G1 Therapeutics Inc. Moses Jennifer K. sold 729 shares of firm against total price of $3942.0 at the cost of $5.41 per share.